Cat. No. 4206
Chemical Name: 4-(5-Methyl-3-phenylisoxazol-4-yl)b
Biological ActivitySelective and potent COX-2 inhibitor (in vitro IC50 values are 0.005 and 140 μM for human recombinant COX-2 and COX-1 respectively). Displays potent anti-inflammatory activity in vivo.
Licensing InformationSold for research purposes under agreement from Pfizer Inc.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Gierse et al (2005) Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity. J.Pharmacol.Exp.Ther. 312 1206. PMID: 15494548.
Walker et al (2001) A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors. Biochem.J. 357 709. PMID: 11463341.
Talley et al (2000) 4-[5-methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J.Med.Chem. 43 775. PMID: 10715145.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Valdecoxib from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Valdecoxib, supplier, cyclooxygenase-2, COX-2, inhibitors, selective, potent, NSAIDs, pfizer, non-steroidal, anti-inflammatory, Tocris Bioscience, Cyclooxygenase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Selective tryptophan 2,3-dioxygenase (TDO) inhibitorNoxA1ds
Potent and selective NADPH oxidase 1 (NOX1) inhibitor
Follow @Tocris on Twitter
Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.